TScan Therapeutics generated modest collaboration revenue in the fourth quarter driven by its Amgen agreement while significantly narrowing its net loss year-over-year due to reduced operating expenses. The company continued advancing its ALLOHA Phase 1 program and strengthened its pipeline with new IND clearances targeting CD45. Cash resources are expected to fund operations into the second half of 2027.

TScan Therapeutics saw revenue increase to $3.1 million in Q2 2025, driven by activity under its Amgen collaboration. However, higher R&D and G&A expenses contributed to a net loss of $37.0 million.

TScan Therapeutics reported a net loss of $34.1 million for the first quarter of 2025, an increase from $30.1 million in the same period last year. Revenue significantly increased to $2.2 million from $0.6 million, primarily due to collaboration activities. The company's cash position remains strong at $251.7 million, expected to fund operations into the first quarter of 2027.

TScan Therapeutics reported a significant decrease in revenue for the fourth quarter of 2024 compared to the same period in 2023, primarily due to the timing of research activities. Despite the revenue decline, the company made substantial progress in its clinical programs, including updated data from the ALLOHA™ heme trial and IND clearance for a new TCR in the PLEXI-T™ solid tumor program. The company also strengthened its financial position with a $30 million registered direct offering and a refinanced debt facility, extending its cash runway into the first quarter of 2027.

TScan Therapeutics reported third quarter 2024 financial results, with revenue at $1.0 million compared to $3.9 million for the same period in 2023. Net loss was $29.9 million, compared to $23.0 million for the third quarter of 2023. Cash, cash equivalents, and marketable securities totaled $271.1 million, expected to fund operations into the fourth quarter of 2026.

TScan Therapeutics reported second quarter 2024 financial results, including revenue of $0.5 million and a net loss of $31.7 million. The company received RMAT designation for TSC-100 and TSC-101 and engaged a CDMO for manufacturing. They expect to report initial data from the solid tumor program and one-year data from the ALLOHATM Phase 1 heme trial by the end of 2024 and cash is expected to fund operations into Q4 2026.

TScan Therapeutics reported a revenue of $0.6 million and a net loss of $30.1 million for the first quarter of 2024. The company dosed the first patient in its Phase 1 solid tumor program and closed an upsized public offering with gross proceeds of $167.8 million, extending the company's cash runway into the fourth quarter of 2026.

TScan Therapeutics reported a revenue of $7.2 million for Q4 2023, compared to $3.1 million for Q4 2022. The net loss for the quarter was $19.6 million, compared to $18.7 million for the same period in 2022. As of December 31, 2023, the company's cash, cash equivalents, and marketable securities totaled $192.0 million.

TScan Therapeutics reported revenue of $3.9 million and a net loss of $23.0 million for the third quarter ended September 30, 2023. The company ended the quarter with $215.4 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2026.

TScan Therapeutics reported a net loss of $24.0 million for the second quarter ended June 30, 2023, compared to a net loss of $15.1 million for the same period in 2022. The company ended the quarter with $208.8 million in cash and cash equivalents. Revenue for the quarter was $3.1 million, compared to $4.1 million for the second quarter ended June 30, 2022.

TScan Therapeutics reported first quarter 2023 financial results, including revenue of $6.8 million and a net loss of $22.6 million. The company highlighted its partnership with Amgen and the progress of its Phase 1 hematologic malignancies study. They ended the quarter with $95.6 million in cash and cash equivalents, extending their cash runway into the third quarter of 2024.

TScan Therapeutics reported a revenue of $3.1 million and a net loss of $18.7 million for the fourth quarter of 2022. The company ended the year with $120.0 million in cash and cash equivalents, expected to fund operations into Q2 2024.

TScan Therapeutics reported Q3 2022 financial results, highlighting progress in their pipeline, including the opening of four sites for their hematologic malignancies program and the completion of a pre-IND meeting with the FDA for their solid tumor program. The company ended the quarter with $137.3 million in cash and cash equivalents, which is expected to fund operations into Q2 2024.

TScan Therapeutics reported a revenue of $4.1 million for the second quarter, primarily driven by research activities related to the collaboration agreement with Novartis. The company's cash and cash equivalents totaled $125.6 million, sufficient to fund operations into 2024. Net loss for the quarter was $15.1 million.

TScan Therapeutics reported a net loss of $16.2 million for the first quarter ended March 31, 2022, with cash and cash equivalents of $140.8 million, sufficient to fund operations into 2024. Revenue for the quarter was $3.0 million, driven by research activities related to the collaboration agreement with Novartis.

TScan Therapeutics reported its full year 2021 financial results, highlighting FDA clearance of IND for TSC-100, the upcoming initiation of a Phase 1 trial for the liquid tumor program, and a strong balance sheet with $161.4 million in cash and cash equivalents.

TScan Therapeutics reported a net loss of $15.8 million for the third quarter of 2021, with research and development expenses at $14.2 million and general and administrative expenses at $4.0 million. The company's cash and cash equivalents totaled $182.3 million as of September 30, 2021, expected to fund operations into 2024. They are advancing their TCR-T therapy candidates, including IND submissions expected for TSC-100 and TSC-101 in Q4 2021.

TScan Therapeutics reported financial results for the quarter ended June 30, 2021. The company had cash and cash equivalents totaling $106.2 million as of June 30, 2021, excluding gross proceeds of $100 million from the IPO. Net loss for the second quarter 2021 was $10.7 million or $7.69 per common share.